Format

Send to

Choose Destination
Alzheimers Dement (Amst). 2018 Nov 13;11:10-18. doi: 10.1016/j.dadm.2018.10.005. eCollection 2019 Dec.

Apolipoprotein E particle size is increased in Alzheimer's disease.

Author information

1
Center for Neurodegenerative Diseases, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.
2
George & Anne Ryan Institute For Neuroscience, University of Rhode Island, Kingston, RI, USA.

Abstract

Introduction:

Apolipoprotein E4 (apoE4) is the predominant risk factor for late-onset Alzheimer's disease (AD), but the question of which structural differences might explain its effect remains unclear.

Methods:

We compared high-density lipoprotein-like apoE particles from 12 AD and 10 control patients using size-exclusion chromatography.

Results:

ApoE particles from patients genotyped as ε4/ε4 were 2.2 ± 0.3 times as massive as particles from ε3/ε3 control subjects and 1.4 ± 0.1 times as massive as particles from ε3/ε3 AD patients. The increased particle size was not because of incorporation of amyloid β or apoE proteolysis products. Particles from AD patients genotyped as ε3/ε3 were 1.59 ± 0.27 times as massive as ε3/ε3 control subjects.

Discussion:

Increased particle size in AD is affected by A PO E genotype and by disease-related differences in assembly or stability. These differences suggest that lipoprotein assembly or stability in AD brain plays an important role in determining apoE4 pathogenicity.

KEYWORDS:

Alzheimer's disease; ApoE; HDL; Size-exclusion HPLC; apolipoprotein E

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center